SAN FRANCISCO, March 17, 2022, Shasqi, a clinical-stage biotechnology company developing precision click chemistry-activated oncology therapeutics, will present updated data from its ongoing Phase 1 clinical study of SQ3370 in patients with advanced solid tumors as well as preclinical data highlighting the activity of its click chemistry-modified protodrug version of monomethyl auristatin E (MMAE), at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022. Presentations and posters will be available for registered attendees for on-demand viewing on the AACR website on April 8, 2022, after 1:00 pm ET.
“We continue to be encouraged by initial data observed from our ongoing Phase 1 study of SQ3370 in heavily pre-treated patients with high disease burden, and we are advancing the development of SQ3370 as a treatment for patients with advanced solid tumors where an anthracycline-containing regimen is appropriate,” said José M. Mejía Oneto, M.D., Ph.D., founder and CEO of Shasqi. “We’ve also demonstrated that our click chemistry platform can activate high doses of MMAE, a commonly used antibody-drug conjugate payload, at the tumor. Our MMAE protodrug achieved good plasma stability, attenuation of cytotoxicity, and was tolerated at doses up to 50-fold higher than the conventional MMAE maximum tolerated dose. We also present the anti-tumor effect of MMAE protodrugs activated at the tumor site using a biopolymer injection. We look forward to studying the anti-tumor efficacy of MMAE protodrugs when targeted to the tumor using biologic approaches.”
Preclinical Poster Title: Click Activated Protodrugs Against Cancer (CAPAC™): A modular platform for tumor-directed oncology therapeutics
Trial-In-Progress Poster Title: SQ3370 in advanced solid tumors: Interim phase 1 results
